Continuing review of an approved and ongoing study posing more than minimal risk that was initially approved by a convened irb:
a. must be conducted by a convened irb.
b. is limited to review of unanticipated problems.
c. must occur within 12 months of the approval date.
d. is not required unless additional risks have been identified.

c. Must occur within 12 months of the approval date.

Explanation:

Continuing review is the term used to refer to the obligation (given by the federal government) to reevaluate any study, or scientific experiment, within 12 months of the study's approval date. Thus, we can state that continuing review of an approved and ongoing study, which represents more than a minimal risk, should occur within 12 months of the study's approval date.

The purpose of a continuing review is to allow the researcher to complete all interactions proposed by his study, avoiding execution errors and incorrect results.

gynecologist i believe